1,377 reports of this reaction
6.9% of all ALPELISIB reports
#2 most reported adverse reaction
RASH is the #2 most commonly reported adverse reaction for ALPELISIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,377 FDA adverse event reports linking ALPELISIB to RASH. This represents approximately 6.9% of all 20,016 adverse event reports for this drug.
Patients taking ALPELISIB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among ALPELISIB users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for ALPELISIB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 1,377 FDA reports for ALPELISIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 6.9% of all adverse event reports for ALPELISIB, making it one of the most commonly reported side effect.
If you experience rash while taking ALPELISIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.